# Cell-type specific effects of the long non-coding RNA HIF1A-AS3 on HIF1A expression in kidney cells

**Authors:** Simone Reichelt-Wurm, Lena Knauss, Bettina Strasser, Mona Scharf, Kathrin Holler, Elke Eggenhofer, Markus Kretz, Bernhard Banas, Miriam C. Banas

PMC · DOI: 10.1038/s41598-025-12441-5 · Scientific Reports · 2025-07-30

## TL;DR

This study explores how a specific long non-coding RNA, HIF1A-AS3, affects HIF1A expression in kidney cells under different conditions, revealing cell-type specific effects.

## Contribution

The paper identifies a cell-type specific regulatory role of HIF1A-AS3 on HIF1A expression in non-cancerous kidney cells.

## Key findings

- HIF1A-AS3 knockdown significantly reduces HIF1A-AS2 and Hif1α in HK-2 cells but not in mesangial cells.
- HIF1A-AS3 RNA is highly stable in HK-2 cells, as shown by Actinomycin D treatment.
- HIF1A-AS3 has a more pronounced effect on HIF1A expression than HIF1A-AS2.

## Abstract

The hypoxia-inducible factor 1α (Hif1α) represents the master transcription factor coordinating cellular responses to oxygen depletion. With hundreds of target genes it plays a key role in numerous bio-medical conditions as well as neoplastic and non-cancerous diseases, which in turn requires a strict regulation. Long non-coding RNAs have the potential to virtually control every step of gene expression. We aimed to investigate the expression and role of HIF1A antisense lncRNAs HIF1A-AS1, AS2, and AS3 under hyperglycemic, hypoxic, or both conditions in three non-cancerous human renal cell types: HK-2 cells, primary RPTECs, and mesangial cells. We observed that HIF1A-AS2 and AS3 expression was upregulated under oxygen deprivation. Furthermore, knockdown (KD) of HIF1A-AS3 resulted in a significant reduction of HIF1A-AS2 and even more important of Hif1α in HK-2 cells but not mesangial cells. While KD of HIF1A also had a diminishing effect on HIF1A-AS2 and AS3 RNA levels, KD of HIF1A-AS2 only affected HIF1A-AS3 but not HIF1A. Treating HK-2 cells with Actinomycin D revealed a high HIF1A-AS3 RNA stability. In conclusion, our data reveal a cell-type specific effect of HIF1A-AS3 on HIF1A RNA and protein expression which might allow the development of a cell-type specific HIF1A antagonist based on lncRNAs.

The online version contains supplementary material available at 10.1038/s41598-025-12441-5.

## Linked entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], HIF1A-AS1 (HIF1A antisense RNA 1) [NCBI Gene 100750246], HIF1A-AS2 (HIF1A antisense RNA 2) [NCBI Gene 100750247], HIF1A-AS3 (HIF1A antisense RNA 3) [NCBI Gene 105370526], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091]
- **Proteins:** HIF1A (hypoxia inducible factor 1 subunit alpha)
- **Chemicals:** Actinomycin D (PubChem CID 457193)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, ACTD (Acetabular dysplasia) [NCBI Gene 780896], ARNT (aryl hydrocarbon receptor nuclear translocator) [NCBI Gene 405] {aka ARNT1, HIF-1-beta, HIF-1beta, HIF1-beta, HIF1B, HIF1BETA}, PPIB (peptidylprolyl isomerase B) [NCBI Gene 5479] {aka CYP-S1, CYPB, HEL-S-39, OI9, SCYLP}, PTGDR (prostaglandin D2 receptor) [NCBI Gene 5729] {aka AS1, ASRT1, DP, DP1, PTGDR1}, EPAS1 (endothelial PAS domain protein 1) [NCBI Gene 2034] {aka ECYT4, HIF2A, HLF, MOP2, PASD2, bHLHe73}, YBX1 (Y-box binding protein 1) [NCBI Gene 4904] {aka BP-8, CBF-A, CSDA2, CSDB, DBPB, EFI-A}, PDS5B (PDS5 cohesin associated factor B) [NCBI Gene 23047] {aka APRIN, AS3, CG008}, HIF1A-AS1 (HIF1A antisense RNA 1) [NCBI Gene 100750246] {aka 5'aHIF-1A, 5'aHIF1alpha, HIF1A-AS3, HIFAL}, MLXIPL (MLX interacting protein like) [NCBI Gene 51085] {aka CHREBP, MIO, MONDOB, WBSCR14, WS-bHLH, bHLHd14}, EGLN3 (egl-9 family hypoxia inducible factor 3) [NCBI Gene 112399] {aka HIFP4H3, HIFPH3, PHD3}
- **Diseases:** respiratory diseases (MESH:D012140), renal non-cancer (MESH:D007680), HG (MESH:D006943), hypoxic (MESH:D002534), HM (MESH:D008228), DKD (MESH:D003928), peripheral arterial disease (MESH:D058729), RPTECs (MESH:D009375), COVID-19 (MESH:D000086382), renal non (MESH:D006030), IRI (MESH:D015427), cancerous (MESH:D009369), hyperglycemic (MESH:D006944), CKD (MESH:D051436), diabetic retinopathy (MESH:D003930), HOX (MESH:D000860), Coxsackievirus B3 infections (OMIM:120050), breast cancer (MESH:D001943), diabetes (MESH:D003920), acute and chronic kidney disease (MESH:D058186)
- **Chemicals:** P (MESH:D010758), PVDF (MESH:C024865), mannitol (MESH:D008353), SDS (MESH:D012967), S (MESH:D013455), streptomycin (MESH:D013307), DMEM 21855 (-), CoCl2 (MESH:C018021), CO2 (MESH:D002245), tryptophan (MESH:D014364), O2 (MESH:D010100), DMSO (MESH:D004121), Actinomycin D (MESH:D003609), TOPO (MESH:C044965), penicillin (MESH:D010406), N2 (MESH:D009584), glucose (MESH:D005947)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HMC — Homo sapiens (Human), Mast cell leukemia, Cancer cell line (CVCL_0003), HMCs — Rattus norvegicus (Rat), Transformed cell line (CVCL_0506), RPTECs — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_K278), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), E.coli — Mus musculus (Mouse), Hybridoma (CVCL_C5CR)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12310967/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12310967/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12310967/full.md

---
Source: https://tomesphere.com/paper/PMC12310967